A Phase 3 interventional study of Alirocumab SAR236553 (REGN727) and Atorvastatin in Hypercholesterolemia, sponsored by Sanofi. Completed at 10 sites in 10 countries. Open to participants aged 8 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-12-29.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.
Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 43rd largest by enrollment, is one of 4 that started in 2018, is one of 20 in phase 3, and was the 38th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 8 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 107 across the 43 interventional studies. Of the 40 that completed or were terminated, 30 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 6 most frequent:
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
38 studies in Hypercholesterolemia by Sanofi: none open now, none under way, none of them phase 3. Of 38 finished, 22 (58%) have results posted.
Among the 38 studies in Hypercholesterolemia by Sanofi, this one is the 38th largest by enrollment, is one of 3 that started in 2018, is one of 22 in phase 3, and was the 36th registered.
Sanofi’s Hypercholesterolemia studies by the year they started, since 2007.
2 of the studies testing alirocumab in Hypercholesterolemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477704Regeneron PharmaceuticalsA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | 2026-12-29 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing alirocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 38 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the efficacy of alirocumab (75 or 150 milligrams [mg] depending on body weight [BW]), administered every 2 weeks (Q2W), on low-density lipoprotein cholesterol (LDL-C) levels at Week 12 of treatment in children and adolescents with homozygous familial hypercholesterolemia (hoFH) of 8 to 17 years of age on top of background treatments.
Secondary Objectives:
The study duration was up to 62 weeks, which included (if needed) a run-in period of up to 4 weeks, a screening period of up to 2 weeks, a treatment period of up to 48 weeks, and a follow-up of 8 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participants potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with BW less than (\<) 50 kilograms (kg) received subcutaneous (SC) injection of alirocumab 75 mg Q2W for 48 weeks. Alirocumab dose was up-titrated to 150 mg Q2W from Week 12 in case of increase in BW with BW greater than or equal to \[\>=\] 50 kg. Participants with BW \>=50 kg received SC injection of alirocumab 150 mg Q2W for 48 weeks.
Drug: Alirocumab SAR236553 (REGN727) · Drug: Atorvastatin · Drug: Simvastatin · Drug: Fluvastatin · Drug: Pravastatin · Drug: Lovastatin · Drug: Rosuvastatin · Drug: Ezetimibe · Drug: Cholestyramine · Drug: Nicotinic acid · Drug: Fenofibrate · Drug: Omega-3 fatty acids
Pharmaceutical form: solution for injection in pre-filled syringe, Route of administration: subcutaneous (SC)
Pharmaceutical form: tablet, Route of administration: oral
Pharmaceutical form: tablet, Route of administration: oral
Pharmaceutical form: capsule, Route of administration: oral
Pharmaceutical form: tablet, Route of administration: oral
Pharmaceutical form: tablet, Route of administration: oral
Pharmaceutical form: tablet, Route of administration: oral
Pharmaceutical form: tablet, Route of administration: oral
Pharmaceutical form: oral suspension, Route of administration: oral
Pharmaceutical form: tablet, Route of administration: oral
Pharmaceutical form: tablet, Route of administration: oral
Pharmaceutical form: capsule, Route of administration: oral
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12: Intent-to-Treat (ITT) Analysis
Adjusted least square (LS) means and standard errors were obtained from the mixed model analysis with repeated measures (MMRM) to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis).
Time frame: Baseline to Week 12
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol at Week 12: On-treatment Analysis
Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline on-treatment data from Week 4 to Week 48 (on-treatment Analysis).
Time frame: Baseline to Week 12
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol at Weeks 24 and 48: ITT Analysis/On-treatment Analysis
Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.
Time frame: Baseline to Weeks 24 and 48
Percent Change From Baseline in Apolipoprotein (Apo) B at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.
Time frame: Baseline to Weeks 12, 24 and 48
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 12, 24 and 48 - ITT Analysis/On-treatment Analysis
Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.
Time frame: Baseline to Weeks 12, 24 and 48
Percent Change From Baseline in Total Cholesterol (Total-C) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Weeks 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.
Time frame: Baseline to Weeks 12, 24 and 48
Percent Change From Baseline in Lipoprotein a (Lp) (a) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
Adjusted means and standard errors were obtained from a multiple imputation approach followed by a robust regression model including all available post-baseline data from Week 4 to Week 48 regardless of status on-or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.
Time frame: Baseline to Weeks 12, 24 and 48
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Weeks 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.
Time frame: Baseline to Weeks 12, 24 and 48
Percent Change From Baseline in Fasting Triglycerides (TG) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
Adjusted means and standard errors were obtained from a multiple imputation approach followed by a robust regression model including all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.
Time frame: Baseline to Weeks 12, 24 and 48
Percent Change From Baseline in Apolipoprotein A1 (Apo A1) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.
Time frame: Baseline to Weeks 12, 24 and 48
Percentage of Participants Reporting >=15 Percent (%) Reduction in LDL-C Level at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
Adjusted Percentage were obtained from a multiple imputation approach for handling of missing data including all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.
Time frame: Baseline to Weeks 12, 24 and 48
Absolute Change From Baseline in LDL-C Level at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.
Time frame: Baseline to Weeks 12, 24 and 48
Number of Participants With Tanner Staging at Baseline, Weeks 12, 24 and 48
Tanner stage defines physical measurements of development in children and adolescent based on external primary and secondary sex characteristics. Participants were evaluated for pubic hair distribution, breast development (only females) and genital development (only males), and classified in 3 categories as: Prepubescent (defined as a person just before start of the development of adult sexual characteristics), Pubescent (defined as a person at or approaching the age of puberty), Postpubescent (sexually mature or a person who has completed puberty).
Time frame: Baseline, Weeks 12, 24 and 48
The study was conducted at 10 active centers (which screened at least 1 participant) in 10 countries worldwide. Overall, 20 participants were screened between 31 August 2018 and 4 January 2019, of whom 2 were screen failures. Of the 10 centers which screened participants, 9 centers enrolled at least 1 participant.
| Milestone | Alirocumab 75 mg Q2W/up to 150 mg Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Started | 9 | 9 |
| Completed | 8 | 9 |
| Not completed | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
Adjusted least square (LS) means and standard errors were obtained from the mixed model analysis with repeated measures (MMRM) to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis).
| percent change | Alirocumab |
|---|---|
| Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12: Intent-to-Treat (ITT) Analysis | -4.1 ± 9.0 |
Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline on-treatment data from Week 4 to Week 48 (on-treatment Analysis).
| percent change | Alirocumab |
|---|---|
| Percent Change From Baseline in Low-Density Lipoprotein Cholesterol at Week 12: On-treatment Analysis | -4.1 ± 9.0 |
Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.
| percent change | Alirocumab |
|---|---|
| Week 24 | -10.1 ± 7.6 |
| Week 48 | 4.2 ± 12.8 |
Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.
| percent change | Alirocumab |
|---|---|
| Week 12 | -4.2 ± 6.8 |
| Week 24 | -11.8 ± 6.1 |
| Week 48 | 0.9 ± 10.4 |
Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.
| percent change | Alirocumab |
|---|---|
| Week 12 | -3.9 ± 8.3 |
| Week 24 | -9.2 ± 7.3 |
| Week 48 | 5.7 ± 13.1 |
Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Weeks 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.
| percent change | Alirocumab |
|---|---|
| Week 12 | -1.9 ± 7.2 |
| Week 24 | -6.3 ± 6.5 |
| Week 48 | 5.5 ± 10.7 |
Adjusted means and standard errors were obtained from a multiple imputation approach followed by a robust regression model including all available post-baseline data from Week 4 to Week 48 regardless of status on-or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.
| percent change | Alirocumab |
|---|---|
| Week 12 | 7.4 ± 7.6 |
| Week 24 | -5.2 ± 8.1 |
| Week 48 | -6.4 ± 12.2 |
Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Weeks 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.
| percent change | Alirocumab |
|---|---|
| Week 12 | 13.0 ± 5.9 |
| Week 24 | 8.9 ± 4.4 |
| Week 48 | 10.1 ± 5.5 |
Adjusted means and standard errors were obtained from a multiple imputation approach followed by a robust regression model including all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.
| percent change | Alirocumab |
|---|---|
| Week 12 | 2.8 ± 8.0 |
| Week 24 | 5.2 ± 16.2 |
| Week 48 | 10.0 ± 8.2 |
Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.
| percent change | Alirocumab |
|---|---|
| Week 12 | 11.3 ± 6.9 |
| Week 24 | 14.6 ± 6.0 |
| Week 48 | 11.3 ± 5.8 |
Adjusted Percentage were obtained from a multiple imputation approach for handling of missing data including all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.
| percentage of participants | Alirocumab |
|---|---|
| Week 12 | 50.0 (26.2 to 73.8) |
| Week 24 | 50.0 (26.2 to 73.8) |
| Week 48 | 39.0 (15.8 to 62.2) |
Adjusted LS means and standard errors were obtained from the MMRM model to account for missing data using all available post-baseline data from Week 4 to Week 48 regardless of status on- or off-treatment used in the model (ITT analysis). Although separate analyses of all available data (ITT analysis) and only data collected within a defined time window (On-treatment analysis) were planned, if all values used in the ITT approach were within the on-treatment time window, the on-treatment analysis would be identical to the ITT analysis, thus the results would be identical and a single outcome measure presenting the results for both types of analysis would be provided.
| mg/dL | Alirocumab |
|---|---|
| Week 12 | -33.4 ± 19.1 |
| Week 24 | -43.0 ± 19.0 |
| Week 48 | -15.0 ± 25.7 |
Tanner stage defines physical measurements of development in children and adolescent based on external primary and secondary sex characteristics. Participants were evaluated for pubic hair distribution, breast development (only females) and genital development (only males), and classified in 3 categories as: Prepubescent (defined as a person just before start of the development of adult sexual characteristics), Pubescent (defined as a person at or approaching the age of puberty), Postpubescent (sexually mature or a person who has completed puberty).
| Participants | Alirocumab 75 mg Q2W/up to 150 mg Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Baseline: Prepubescent | 3 | 0 |
| Baseline: Pubescent | 6 | 9 |
| Baseline: Post-pubescent | 0 | 0 |
| Week 12: Prepubescent | 3 | 0 |
| Week 12: Pubescent | 6 | 8 |
| Week 12: Post-pubescent | 0 | 1 |
| Week 24: Prepubescent | 2 | 0 |
| Week 24: Pubescent | 6 | 8 |
| Week 24: Post-pubescent | 0 | 1 |
| Week 48: Prepubescent | 1 | 0 |
| Week 48: Pubescent | 7 | 7 |
| Week 48: Post-pubescent | 0 | 2 |
Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to 56 weeks of the study regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alirocumab 75 mg Q2W/up to 150 mg Q2W | 1/9 (11.1%) | 1/9 (11.1%) | 8/9 (88.9%) |
| Alirocumab 150 mg Q2W | 0/9 (0%) | 0/9 (0%) | 9/9 (100%) |
| Event | Alirocumab 75 mg Q2W/up to 150 mg Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Cardiac FailureCardiac disorders | 1/9 | 0/9 |
| Event | Alirocumab 75 mg Q2W/up to 150 mg Q2W | Alirocumab 150 mg Q2W |
|---|---|---|
| Aortic Valve IncompetenceCardiac disorders | 2/9 | 1/9 |
| InfluenzaInfections and infestations | 2/9 | 0/9 |
| NasopharyngitisInfections and infestations | 1/9 | 2/9 |
| HeadacheNervous system disorders | 2/9 | 1/9 |
| SplenomegalyBlood and lymphatic system disorders | 1/9 | 0/9 |
| Bicuspid Aortic ValveCongenital, familial and genetic disorders | 0/9 | 1/9 |
| DiarrhoeaGastrointestinal disorders | 0/9 | 1/9 |
| NauseaGastrointestinal disorders | 1/9 | 0/9 |
| VomitingGastrointestinal disorders | 1/9 | 0/9 |
| FatigueGeneral disorders | 1/9 | 0/9 |
Analysis was performed on all enrolled participants.
| Age, Continuous(years) | Alirocumab 75 mg Q2W/up to 150 mg Q2W | Alirocumab 150 mg Q2W | Total |
|---|---|---|---|
| Mean | 10.4 ± 1.5 | 14.3 ± 2.4 | 12.4 ± 2.8 |
| Sex: Female, Male(Participants) | Alirocumab 75 mg Q2W/up to 150 mg Q2W | Alirocumab 150 mg Q2W | Total |
|---|---|---|---|
| Female | 4 | 5 | 9 |
| Male | 5 | 4 | 9 |
| Race (NIH/OMB)(Participants) | Alirocumab 75 mg Q2W/up to 150 mg Q2W | Alirocumab 150 mg Q2W | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 3 |
| Asian | 1 | 2 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 6 | 5 | 11 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Low-Density Lipoprotein Cholesterol (LDL-C)(milligrams per deciliter (mg/dL)) | Alirocumab 75 mg Q2W/up to 150 mg Q2W | Alirocumab 150 mg Q2W | Total |
|---|---|---|---|
| Mean | 437.7 ± 192.8 | 308.3 ± 181.6 | 373.0 ± 193.5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2018 to primary completion in Feb 2020, 17 months.
Results were first posted in Dec 2020, 10 months after primary completion.
Of 123 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 17 months is close to that.
Counting every sponsor, half of 126 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alirocumab · Atorvastatin · Simvastatin · Fluvastatin · Pravastatin · Lovastatin · Rosuvastatin · Ezetimibe · Cholestyramine Resin · Niacin · Fenofibrate · Omega-3 fatty acid